Free Access
Med Sci (Paris)
Volume 30, Number 1, Janvier 2014
Page(s) 33 - 35
Section Nouvelles
Published online 24 January 2014
  1. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012 ; 56 : S88–100. [CrossRef] [PubMed] [Google Scholar]
  2. Edlin BR. Perspective: test and treat this silent killer. Nature 2011 ; 474 : S18–S19. [CrossRef] [PubMed] [Google Scholar]
  3. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009 ; 119 : 1745–1754. [CrossRef] [PubMed] [Google Scholar]
  4. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011 ; 239 : 99–108. [CrossRef] [PubMed] [Google Scholar]
  5. Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010 ; 139 : 965–974. [CrossRef] [PubMed] [Google Scholar]
  6. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011 ; 204 : 811–813. [CrossRef] [PubMed] [Google Scholar]
  7. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012 ; 4 : 115ra1. [CrossRef] [PubMed] [Google Scholar]
  8. Sominskaya I, Alekseeva E, Skrastina D, et al. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol Immunol 2006 ; 43 : 1941–1952. [CrossRef] [PubMed] [Google Scholar]
  9. Garrone P, Fluckiger AC, Mangeot PE, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011 ; 3 : 94ra71. [CrossRef] [PubMed] [Google Scholar]
  10. Legrand-Abravanel F, Izopet J. Culture du virus de l’hépatite C, enfin ! Med Sci (Paris) 2007 ; 23 : 588–589. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  11. Akazawa D, Moriyama M, Yokokawa H, et al. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 2013 ; 145 : 447–455. [CrossRef] [PubMed] [Google Scholar]
  12. Phogat S, Svehla K, Tang M, et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008 ; 373 : 72–84. [CrossRef] [PubMed] [Google Scholar]
  13. Beaumont E, Patient R, Hourioux C, et al. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 2013 ; 57 : 1303–1313. [CrossRef] [PubMed] [Google Scholar]
  14. Pol S. Virus de l’hépatite C : 25 ans, la fin de l’histoire ? Med Sci (Paris) 2013 ; 29 : 998–1003. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.